BC Innovations | May 7, 2019
Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
BC Innovations | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
BC Innovations | Dec 20, 2017
Distillery Techniques

Drug platforms

TECHNOLOGY: Gene therapy An ADARB2-based method of editing RNA could help treat diseases caused by point mutations, such as Rett syndrome and X-linked nephrogenic diabetes insipidus. The method repairs disease-associated G to A mutations in...
BC Innovations | Nov 21, 2013
Distillery Therapeutics

Indication: Neurology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Amyotrophic lateral sclerosis (ALS) Chromosome 9 open reading frame 72 (C9orf72) Studies in patient samples and mice suggest antisense oligonucleotides targeting...
BC Innovations | Nov 7, 2013
Cover Story

ALS antisense oligonucleotides

Isis Pharmaceuticals Inc. has teamed up with a trio of academic groups to develop antisense therapeutics for the largest subset of patients with amyotrophic lateral sclerosis, 1-3 and all three teams have converged on a...
Items per page:
1 - 5 of 5